Marker Therapeutics Inc (MRKR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.90-11.34%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · MRKR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -67.7% |
| Our one-year growth estimate | diamond | -49.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 18.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
Why it matters: Management lists extending cash runway through Q4 2026 as a priority. The FDA grant adds $2.6 million, but the supplied figures do not show cash on hand.
Worry ifThe next company update says cash is expected to last through Q4 2026 or longer, with the $2.6 million grant included.
Less concerning ifThe next company update says cash may run out before Q4 2026, or reports a financing need before then.
Why it matters: The supplied figures show a $2.62 million operating loss in Q2. A new loss figure can show whether spending is changing as the program advances.
Watch forThe Nov. 12 update reports a lower operating loss than $2.62 million for Q2.
Also watch forThe Nov. 12 update reports an operating loss above $2.62 million for Q2.
Why it matters: The company named Q1 2027 as its target start. Starting on time would move its top program into a company-run trial.
Supportive ifThe company announces that its Phase 1 MT-601 pancreatic cancer study has begun by March 31, 2027.
Worry ifThe study has not begun by March 31, 2027, or the company reports a delay beyond Q1 2027.
Why it matters: The earlier Baylor study reported an 84.6% disease control rate. New results can test whether the company’s study supports that signal.
Supportive ifThe company reports patient results. They show disease control and safety like the prior Baylor study.
Worry ifThe company reports no disease control or serious safety problems. Results are not below the prior study’s 84.6% disease control rate.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$296 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $800 loss on $10,000 · 8.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,935 loss on $10,000 · 59.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.